PT  - JOURNAL ARTICLE
AU  - Lendrem, Dennis
AU  - Mitchell, Sheryl
AU  - McMeekin, Peter
AU  - Bowman, Simon
AU  - Price, Elizabeth
AU  - Pease, Colin T
AU  - Emery, Paul
AU  - Andrews, Jacqueline
AU  - Lanyon, Peter
AU  - Hunter, John
AU  - Gupta, Monica
AU  - Bombardieri, Michele
AU  - Sutcliffe, Nurhan
AU  - Pitzalis, Costantino
AU  - McLaren, John
AU  - Cooper, Annie
AU  - Regan, Marian
AU  - Giles, Ian
AU  - Isenberg, David
AU  - Vadivelu, Saravanan
AU  - Coady, David
AU  - Dasgupta, Bhaskar
AU  - McHugh, Neil
AU  - Young-Min, Steven
AU  - Moots, Robert
AU  - Gendi, Nagui
AU  - Akil, Mohammed
AU  - Griffiths, Bridget
AU  - Ng, Wan-Fai
AU  - on behalf of the UK primary Sjögren's Syndrome Registry
TI  - Health-related utility values of patients with primary Sjögren's syndrome and its predictors
AID  - 10.1136/annrheumdis-2012-202863
DP  - 2014 Jul 01
TA  - Annals of the Rheumatic Diseases
PG  - 1362--1368
VI  - 73
IP  - 7
4099  - http://ard.bmj.com/content/73/7/1362.short
4100  - http://ard.bmj.com/content/73/7/1362.full
SO  - Ann Rheum Dis2014 Jul 01; 73
AB  - Objectives EuroQoL-5 dimension (EQ-5D) is a standardised preference-based tool for measurement of health-related quality of life and EQ-5D utility values can be converted to quality-adjusted life years (QALYs) to aid cost-utility analysis. This study aimed to evaluate the EQ-5D utility values of 639 patients with primary Sjögren's syndrome (PSS) in the UK. Methods Prospective data collected using a standardised pro forma were compared with UK normative data. Relationships between utility values and the clinical and laboratory features of PSS were explored. Results The proportion of patients with PSS reporting any problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression were 42.2%, 16.7%, 56.6%, 80.6% and 49.4%, respectively, compared with 5.4%, 1.6%, 7.9%, 30.2% and 15.7% for the UK general population. The median EQ-5D utility value was 0.691 (IQR 0.587–0.796, range −0.239 to 1.000) with a bimodal distribution. Bivariate correlation analysis revealed significant correlations between EQ-5D utility values and many clinical features of PSS, but most strongly with pain, depression and fatigue (R values>0.5). After adjusting for age and sex differences, multiple regression analysis identified pain and depression as the two most important predictors of EQ-5D utility values, accounting for 48% of the variability. Anxiety, fatigue and body mass index were other statistically significant predictors, but they accounted for <5% in variability. Conclusions This is the first report on the EQ-5D utility values of patients with PSS. These patients have significantly impaired utility values compared with the UK general population. EQ-5D utility values are significantly related to pain and depression scores in PSS.